Cathie Wood's $22M Biotech Shuffle, Dumps One Stock for 21st Straight Session While Other Bets Pile Up
Cathie Wood's ARK dumps $18M of Twist Bioscience while buying Recursion, Veracyte and Intellia, extending its CRISPR bet to 50 sessions.
Stocks · News reference
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Cathie Wood's ARK dumps $18M of Twist Bioscience while buying Recursion, Veracyte and Intellia, extending its CRISPR bet to 50 sessions.
A look at the stocks that are owned by Cathie Wood's Ark Invest and Donald Trump.
Cathie Wood’s ARKG bought Ionis, Beam, Veracyte and Scribe Therapeutics. Here are the biotech ETFs that also hold her latest bets.
Tempus AI stock pulled back Friday but stays firmly above key moving averages. Is the TEM rally still intact? Read more.
Moderna’s cancer vaccine breakthrough puts biotech, mRNA and genomics ETFs in focus. Here are the funds worth watching.
Cathie Wood's Ark Invest added to positions in Nvidia, Broadcom, and Intellia Therapeutics on Friday as these stocks declined. Nvidia exceeded earnings expectations with 106% revenue growth and raised guidance to 70% for fiscal 2028, now trading at 14x forward earnings. Broadcom is on track for accelerating growth with an upcoming earnings report. Intellia, a gene-editing biotech, has declined over 50% from recent highs but remains well-funded with analyst support.